Doximity (DOCS) Stock Forecast, Price Target & Predictions
DOCS Stock Forecast
Doximity stock forecast is as follows: an average price target of $32.17 (represents a -19.90% downside from DOCS’s last price of $40.16) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
DOCS Price Target
The average price target for Doximity (DOCS) is $32.17 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $39.00 to $25.00. This represents a potential -19.90% downside from DOCS's last price of $40.16.
DOCS Analyst Ratings
According to 6 Wall Street analysts, Doximity's rating consensus is 'Buy'. The analyst rating breakdown for DOCS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (50.00%), 2 'Hold' (33.33%), 1 'Sell' (16.67%), and 0 'Strong Sell' (0.00%).
Doximity Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 09, 2024 | Scott Berg | Needham | $38.00 | $25.66 | 48.09% | -5.38% |
| May 17, 2024 | Stephanie Davis | Barclays | $31.00 | $27.89 | 11.15% | -22.81% |
| May 17, 2024 | Jailendra Singh | Truist Financial | $31.00 | $23.74 | 30.58% | -22.81% |
| May 17, 2024 | Elizabeth Anderson | Evercore ISI | $29.00 | $23.74 | 22.16% | -27.79% |
| Apr 23, 2024 | Craig Hettenbach | Morgan Stanley | $25.00 | $25.01 | -0.04% | -37.75% |
| Apr 01, 2024 | Elizabeth Anderson | Evercore ISI | $30.00 | $26.41 | 13.59% | -25.30% |
| Oct 23, 2022 | Elizabeth Anderson | Evercore ISI | $28.00 | $25.02 | 11.91% | -30.28% |
| Aug 05, 2022 | Jessica Tassan | Piper Sandler | $39.00 | $40.31 | -3.25% | -2.89% |
The latest Doximity stock forecast, released on Aug 09, 2024 by Scott Berg from Needham, set a price target of $38.00, which represents a 48.09% increase from the stock price at the time of the forecast ($25.66), and a -5.38% decrease from DOCS last price ($40.16).
Doximity Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 6 |
| Avg Price Target | - | $38.00 | $30.67 |
| Last Closing Price | $40.16 | $40.16 | $40.16 |
| Upside/Downside | -100.00% | -5.38% | -23.63% |
In the current month, the average price target of Doximity stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Doximity's last price of $40.16. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 20, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 09, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
| Aug 09, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 18, 2024 | Wells Fargo | Neutral | Neutral | Hold |
| Jul 18, 2024 | Evercore ISI | Underperform | Underperform | Hold |
| Jul 18, 2024 | Wells Fargo | Market Perform | Underweight | Downgrade |
| May 17, 2024 | Evercore ISI | Perform | Perform | Hold |
| Apr 23, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
| Apr 02, 2024 | Leerink Partners | Underperform | Underperform | Hold |
| Apr 02, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
Doximity's last stock rating was published by Jefferies on Aug 20, 2024. The company gave DOCS a "Buy" rating, the same as its previous rate.
Doximity Financial Forecast
Doximity Revenue Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $135.28M | $113.61M | $108.47M | $110.97M | $115.26M | $102.19M | - | $93.65M | $97.88M | $79.35M | $72.67M |
| Avg Forecast | $146.93M | $162.50M | $149.24M | $147.50M | $137.21M | $153.02M | $137.28M | $135.87M | $125.83M | $140.27M | $127.08M | $119.88M | $116.41M | $127.50M | $109.05M | $107.00M | $110.09M | $111.28M | $100.15M | $89.61M | $90.14M | $86.26M | $73.49M | $63.62M |
| High Forecast | $147.30M | $162.91M | $149.61M | $147.88M | $137.56M | $153.40M | $137.62M | $136.21M | $126.15M | $140.62M | $127.43M | $120.19M | $116.70M | $128.11M | $109.66M | $107.27M | $110.37M | $111.56M | $100.41M | $89.61M | $93.43M | $89.41M | $76.18M | $65.94M |
| Low Forecast | $146.60M | $162.14M | $148.91M | $147.18M | $136.91M | $152.68M | $136.97M | $135.57M | $125.55M | $139.96M | $126.93M | $119.62M | $116.15M | $127.10M | $108.56M | $106.76M | $109.85M | $111.04M | $99.93M | $89.61M | $87.59M | $83.82M | $71.42M | $61.82M |
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.01% | 1.01% | 1.04% | 1.02% | - | 1.04% | 1.13% | 1.08% | 1.14% |
Doximity's average Quarter revenue forecast for Mar 24 based on 4 analysts is $116.41M, with a low forecast of $116.15M, and a high forecast of $116.70M. DOCS's average Quarter revenue forecast represents a -13.95% decrease compared to the company's last Quarter revenue of $135.28M (Dec 23).
Doximity EBITDA Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $58.55M | $33.79M | $32.29M | $35.55M | $41.10M | $34.69M | - | $29.29M | $37.17M | $26.53M | $26.07M |
| Avg Forecast | $44.81M | $49.56M | $45.52M | $44.99M | $41.85M | $46.67M | $41.87M | $41.44M | $38.38M | $42.78M | $38.76M | $36.56M | $21.25M | $38.88M | $33.26M | $32.63M | $19.32M | $33.94M | $24.32M | $27.33M | $17.56M | $24.53M | $22.11M | $24.05M |
| High Forecast | $44.92M | $49.68M | $45.63M | $45.10M | $41.95M | $46.79M | $41.97M | $41.54M | $38.47M | $42.89M | $38.86M | $36.65M | $25.50M | $39.07M | $33.45M | $32.71M | $23.18M | $34.02M | $29.18M | $27.33M | $21.08M | $29.44M | $26.53M | $28.86M |
| Low Forecast | $44.71M | $49.45M | $45.41M | $44.89M | $41.76M | $46.56M | $41.77M | $41.35M | $38.29M | $42.68M | $38.71M | $36.48M | $17.00M | $38.76M | $33.11M | $32.56M | $15.46M | $33.86M | $19.45M | $27.33M | $14.05M | $19.63M | $17.69M | $19.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.51% | 1.02% | 0.99% | 1.84% | 1.21% | 1.43% | - | 1.67% | 1.52% | 1.20% | 1.08% |
4 analysts predict DOCS's average Quarter EBITDA for Mar 24 to be $21.25M, with a high of $25.50M and a low of $17.00M. This is -63.70% lower than Doximity's previous annual EBITDA (Dec 23) of $58.55M.
Doximity Net Income Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $47.96M | $30.60M | $28.41M | $30.67M | $33.47M | $26.30M | - | $36.73M | $55.65M | $36.09M | $26.32M |
| Avg Forecast | - | - | - | - | $52.30M | $62.01M | $52.55M | $52.30M | $47.11M | $55.47M | $50.81M | $44.46M | $26.66M | $47.48M | $33.41M | $28.47M | $24.24M | $34.98M | $33.08M | $20.14M | $22.04M | $36.73M | $30.07M | $24.28M |
| High Forecast | - | - | - | - | $52.47M | $62.21M | $52.72M | $52.47M | $47.26M | $55.66M | $52.77M | $44.61M | $32.00M | $49.46M | $37.12M | $28.56M | $29.09M | $35.09M | $39.70M | $20.14M | $26.44M | $44.07M | $36.09M | $29.14M |
| Low Forecast | - | - | - | - | $52.15M | $61.83M | $52.39M | $52.15M | $46.97M | $55.31M | $46.90M | $44.34M | $21.33M | $43.52M | $29.70M | $28.39M | $19.39M | $34.88M | $26.46M | $20.14M | $17.63M | $29.38M | $24.06M | $19.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 0.92% | 1.00% | 1.27% | 0.96% | 0.79% | - | 1.67% | 1.52% | 1.20% | 1.08% |
Doximity's average Quarter net income forecast for Mar 24 is $26.66M, with a range of $21.33M to $32.00M. DOCS's average Quarter net income forecast represents a -44.40% decrease compared to the company's last Quarter net income of $47.96M (Dec 23).
Doximity SG&A Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $44.60M | $39.17M | $43.70M | $42.91M | $42.73M | $37.77M | - | $36.54M | $34.78M | $29.99M | $26.57M |
| Avg Forecast | $55.73M | $61.64M | $56.61M | $55.95M | $52.05M | $58.05M | $52.07M | $51.54M | $47.73M | $53.21M | $48.20M | $45.48M | $26.53M | $48.36M | $41.37M | $40.59M | $24.12M | $42.21M | $27.49M | $33.99M | $21.93M | $22.95M | $24.99M | $24.51M |
| High Forecast | $55.87M | $61.80M | $56.75M | $56.09M | $52.18M | $58.19M | $52.20M | $51.67M | $47.85M | $53.34M | $48.34M | $45.59M | $31.84M | $48.60M | $41.60M | $40.69M | $28.94M | $42.32M | $32.99M | $33.99M | $26.31M | $27.54M | $29.99M | $29.41M |
| Low Forecast | $55.61M | $61.51M | $56.49M | $55.83M | $51.94M | $57.92M | $51.96M | $51.43M | $47.63M | $53.09M | $48.15M | $45.38M | $21.22M | $48.21M | $41.18M | $40.50M | $19.29M | $42.12M | $21.99M | $33.99M | $17.54M | $18.36M | $19.99M | $19.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.95% | 1.08% | 1.78% | 1.01% | 1.37% | - | 1.67% | 1.52% | 1.20% | 1.08% |
Doximity's average Quarter SG&A projection for Mar 24 is $26.53M, based on 4 Wall Street analysts, with a range of $21.22M to $31.84M. The forecast indicates a -40.51% fall compared to DOCS last annual SG&A of $44.60M (Dec 23).
Doximity EPS Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 4 | 8 | 11 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 5 | 6 | 12 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.26 | $0.16 | $0.15 | $0.16 | $0.17 | $0.14 | - | $0.19 | $0.30 | $0.19 | $0.30 |
| Avg Forecast | - | - | - | - | $0.26 | $0.31 | $0.26 | $0.26 | $0.24 | $0.28 | $0.26 | $0.22 | $0.20 | $0.24 | $0.17 | $0.14 | $0.17 | $0.18 | $0.15 | $0.10 | $0.15 | $0.11 | $0.09 | $0.06 |
| High Forecast | - | - | - | - | $0.26 | $0.31 | $0.26 | $0.26 | $0.24 | $0.28 | $0.26 | $0.22 | $0.20 | $0.25 | $0.19 | $0.14 | $0.17 | $0.18 | $0.15 | $0.10 | $0.15 | $0.12 | $0.09 | $0.07 |
| Low Forecast | - | - | - | - | $0.26 | $0.31 | $0.26 | $0.26 | $0.24 | $0.28 | $0.24 | $0.22 | $0.20 | $0.22 | $0.15 | $0.14 | $0.17 | $0.18 | $0.15 | $0.10 | $0.14 | $0.11 | $0.08 | $0.06 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 0.95% | 1.05% | 0.93% | 0.97% | 0.93% | - | 1.29% | 2.69% | 2.18% | 4.71% |
According to 4 Wall Street analysts, Doximity's projected average Quarter EPS for Mar 24 is $0.20, with a low estimate of $0.20 and a high estimate of $0.20. This represents a -22.82% decrease compared to DOCS previous annual EPS of $0.26 (Dec 23).
Doximity Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TDOC | Teladoc Health | $9.11 | $52.65 | 477.94% | Hold |
| ACCD | Accolade | $4.31 | $14.81 | 243.62% | Buy |
| CERT | Certara | $10.83 | $21.75 | 100.83% | Hold |
| DH | Definitive Healthcare | $4.74 | $9.50 | 100.42% | Hold |
| TXG | 10x Genomics | $21.41 | $30.20 | 41.06% | Hold |
| SDGR | Schrödinger | $19.62 | $27.33 | 39.30% | Buy |
| PGNY | Progyny | $24.82 | $34.50 | 39.00% | Hold |
| HQY | HealthEquity | $78.80 | $97.00 | 23.10% | Buy |
| GEHC | GE HealthCare | $86.79 | $93.88 | 8.17% | Buy |
| VEEV | Veeva Systems | $214.80 | $229.50 | 6.84% | Buy |
| AMWL | American Well | $10.15 | $8.40 | -17.24% | Hold |
| DOCS | Doximity | $40.16 | $32.17 | -19.90% | Buy |
DOCS Forecast FAQ
Is Doximity a good buy?
Yes, according to 6 Wall Street analysts, Doximity (DOCS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 50.00% of DOCS's total ratings.
What is DOCS's price target?
Doximity (DOCS) average price target is $32.17 with a range of $25 to $39, implying a -19.90% from its last price of $40.16. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Doximity stock go up soon?
According to Wall Street analysts' prediction for DOCS stock, the company can go down by -19.90% (from the last price of $40.16 to the average price target of $32.17), down by -2.89% based on the highest stock price target, and down by -37.75% based on the lowest stock price target.
Can Doximity stock reach $60?
DOCS's average twelve months analyst stock price target of $32.17 does not support the claim that Doximity can reach $60 in the near future.
What are Doximity's analysts' financial forecasts?
Doximity's analysts financial forecasts for the fiscal year (Mar 2026) are as follows: average revenue is $563.38M (high $564.79M, low $562.13M), average EBITDA is $171.82M (high $172.25M, low $171.44M), average net income is $219.15M (high $219.86M, low $218.52M), average SG&A $213.71M (high $214.25M, low $213.24M), and average EPS is $1.1 (high $1.1, low $1.1). DOCS's analysts financial forecasts for the fiscal year (Mar 2027) are as follows: average revenue is $606.17M (high $607.7M, low $604.83M), average EBITDA is $184.87M (high $185.34M, low $184.46M), average net income is $0 (high $0, low $0), average SG&A $229.94M (high $230.52M, low $229.43M), and average EPS is $0 (high $0, low $0).
Did the DOCS's actual financial results beat the analysts' financial forecasts?
Based on Doximity's last annual report (Mar 2023), the company's revenue was $419.05M, beating the average analysts forecast of $411.14M by 1.92%. Apple's EBITDA was $135.39M, beating the average prediction of $104.91M by 29.06%. The company's net income was $112.82M, beating the average estimation of $112.43M by 0.34%. Apple's SG&A was $160.27M, beating the average forecast of $127.81M by 25.39%. Lastly, the company's EPS was $0.58, missing the average prediction of $0.599 by -3.13%. In terms of the last quarterly report (Dec 2023), Doximity's revenue was $135.28M, beating the average analysts' forecast of $127.5M by 6.11%. The company's EBITDA was $58.55M, beating the average prediction of $38.88M by 50.58%. Doximity's net income was $47.96M, beating the average estimation of $47.48M by 1.00%. The company's SG&A was $44.6M, missing the average forecast of $48.36M by -7.79%. Lastly, the company's EPS was $0.26, beating the average prediction of $0.238 by 9.09%